Latest & greatest articles for glyburide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on glyburide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on glyburide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for glyburide

1. Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin

Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Article Text Therapeutics/Prevention Systematic review with meta analysis In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Dana Carroll , Kristi W Kelley

2015 Evidence-Based Medicine

2. A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS

A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS (GRACES) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02080377 Recruitment Status : Completed First Posted

2014 Clinical Trials

3. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. (Abstract)

Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. Carvedilol is available in clinical practice as a racemate in which (S)-(-)-carvedilol is a β- and α1 -adrenergic antagonist and (R)-(+)-carvedilol is only an α1 -adrenergic antagonist. Carvedilol is mainly metabolized by glucuronidation, by CYP2D6 to hydroxyphenylcarvedilol (OHC), and by CYP2C9 to O-desmethylcarvedilol (DMC). This study evaluated (...) the pharmacokinetics of carvedilol enantiomers and their metabolites OHC and DMC in healthy volunteers (n = 13) and in type 2 diabetes mellitus patients with good glycemic control (n = 13). The healthy subjects were enrolled to receive either a 25-mg oral single dose of carvedilol alone (no DDI) or carvedilol simultaneously with 5 mg glibenclamide and 500 mg metformin (DDI), whereas type 2 diabetes mellitus patients who were on long-term treatment with glibenclamide (5 mg/8 h) and metformin (500 mg/8 h) were

2018 Journal of clinical pharmacology Controlled trial quality: uncertain

4. Glibenclamide (Amglidia) - Diabetes Mellitus

Glibenclamide (Amglidia) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 22 February 2018 EMA/153558/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Amglidia International non (...) -proprietary name: glibenclamide Procedure No. EMEA/H/C/004379/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. CHMP assessment report EMA/153558/2018 Page 2/60 Administrative information Name of the medicinal product: Amglidia Applicant: Ammtek 15, rue Beranger 75003 Paris FRANCE Active substance: GLIBENCLAMIDE International Nonproprietary Name: glibenclamide Pharmaco-therapeutic group (ATC Code): BLOOD GLUCOSE LOWERING DRUGS, EXCL

2018 European Medicines Agency - EPARs

5. Low dosE GlibENclamide in Diabetes Part A

. At the end of the retention period (currently 5 years), the data will be deleted from the archive. Keywords provided by University of Oxford: diabetes glibenclamide glucagon Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Glyburide Hypoglycemic Agents Physiological Effects of Drugs (...) Low dosE GlibENclamide in Diabetes Part A Low dosE GlibENclamide in Diabetes Part A - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Low dosE GlibENclamide in Diabetes Part A (LEGEND-A) The safety

2016 Clinical Trials

6. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. (Abstract)

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Glycemic excursion is significantly associated with oxidative stress, which plays a role in the development of chronic complications in type 2 diabetes mellitus (T2DM). Acarbose has been reported to reduce cardiovascular risk in patients with impaired glucose tolerance and T2DM. We (...) hypothesize that treatment with acarbose could attenuate glycemic excursions and reduce oxidative stress in patients with T2DM.This study aimed to evaluate the effects of acarbose versus glibenclamide on mean amplitude of glycemic excursions (MAGE) and oxidative stress in patients with T2DM who are insufficiently controlled by metformin.T2DM outpatients aged 30 to 70 years who were taking single or dual oral antidiabetic drugs for ≥3 months and had a glycosylated hemoglobin (HbA(1c)) value between 7.0

2011 Clinical therapeutics Controlled trial quality: uncertain

7. Comparative efficacy and safety of metformin, glyburide and insulin in treating gestational diabetes mellitus: a meta-analysis

Comparative efficacy and safety of metformin, glyburide and insulin in treating gestational diabetes mellitus: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

8. Efficacy And Safety of Antidiabetic Drugs Available on Brazilian Public Health System (Sus) - Regular Insulin, Nph Insulin, Metformin, Glibenclamide And Gliclazide - In Treatment of Type 2 Diabetes (T2dm) - Systematic Review And Meta-Analysis. Full Text available with Trip Pro

Efficacy And Safety of Antidiabetic Drugs Available on Brazilian Public Health System (Sus) - Regular Insulin, Nph Insulin, Metformin, Glibenclamide And Gliclazide - In Treatment of Type 2 Diabetes (T2dm) - Systematic Review And Meta-Analysis. 26534614 2016 02 04 2015 11 04 1524-4733 18 7 2015 Nov Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Value Health Efficacy And Safety of Antidiabetic Drugs Available on Brazilian Public Health (...) System (Sus) - Regular Insulin, Nph Insulin, Metformin, Glibenclamide And Gliclazide - In Treatment of Type 2 Diabetes (T2dm) - Systematic Review And Meta-Analysis. A862 10.1016/j.jval.2015.09.499 S1098-3015(15)02575-9 Alvares J J College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil. Araujo V E VE College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil. Izidoro J B JB College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil

2015 Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

9. Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety

Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety | CADTH.ca Find the information you need Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Glyburide, Gliclazide or Glimepiride (...) for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Published on: August 20, 2015 Project Number: RC0693-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of glyburide versus gliclazide or glimepiride in elderly patients with type 2 diabetes? What is the clinical evidence regarding the safety of glyburide, gliclazide or glimepiride in elderly

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy]. (Abstract)

[Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy]. To evaluate the efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus (DM2) with secondary failure to glibenclamide.A randomized, double-blind, multicentric trial was carried out in 104 obese patients with DM2 (...) , fasting glucose > 140 mg/dL and glycated hemoglobin A1c (A1C) > 8%, in spite of treatment with glibenclamide at maximum doses and medical nutrition therapy for at least the 3 months previous to the study. After randomization, the patients received in titrated way during 3 months one of the following treatments: up to 4 mg of glimepiride, 2 g of metformin or 4 mg of glimepiride plus 2 g of metformin in a single presentation. Efficacy criteria were either a decrease in A1C of 1% or more, or a reduction

2004 Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición Controlled trial quality: uncertain

11. Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety

Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions There was no evidence identified concerning the clinical effectiveness of glyburide when

2011 Health Technology Assessment (HTA) Database.

12. Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. (Abstract)

Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors, used to treat type 2 diabetes (T2DM), improve endothelial function. The current study investigated the effects of vildagliptin, a DPP-4 inhibitor, compared to glibenclamide on endothelial function, arterial stiffness, and blood pressure in patients (...) with T2DM and hypertension.Patients aged over 35 years with T2DM and hypertension, but without cardiovascular disease, were randomly allocated to treatment with vildagliptin (n = 25) or glibenclamide (n = 25). Both groups took metformin. Endothelial function was evaluated by peripheral artery tonometry (Endo-PAT 2000) to calculate the reactive hyperemia index (RHI) and arterial stiffness. Primary outcome was change in the RHI after 12 weeks of treatment. Twenty-four-hour non-invasive ambulatory blood

2019 Acta diabetologica Controlled trial quality: uncertain

13. Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial. Full Text available with Trip Pro

Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial. Metformin is widely used to treat gestational diabetes (GDM), but many women remain hyperglycaemic and require additional therapy. We aimed to determine recruitment rate and participant throughput in a randomised trial of glibenclamide compared with standard therapy insulin (added to maximum tolerated metformin) for treatment of GDM.We conducted an open label feasibility (...) study in 5 UK antenatal clinics among pregnant women 16 to 36 weeks' gestation with metformin-treated GDM. Women failing to achieve adequate glycaemic control on metformin monotherapy were randomised to additional glibenclamide or insulin. The primary outcome was recruitment rate. We explored feasibility with uptake, retention, adherence, safety, glycaemic control, participant satisfaction and clinical outcomes.Records of 197 women were screened and 23 women randomised to metformin and glibenclamide

2017 BMC Pregnancy and Childbirth Controlled trial quality: predicted high

14. Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 (...) and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide (n=460) or insulin (n=454). The starting dosage for glyburide was 2.5 mg orally once per day and could be increased if necessary 4 days later by 2.5 mg and thereafter

2018 JAMA Controlled trial quality: predicted high

15. Fetal, neonatal, and childhood outcomes of pregnancies affected by gestational diabetes mellitus treated with glyburide (glibenclamide)

Fetal, neonatal, and childhood outcomes of pregnancies affected by gestational diabetes mellitus treated with glyburide (glibenclamide) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

16. Glibenclamide

Glibenclamide USE OF GLIBENCLAMIDE IN PREGNANCY 0344 892 0909 USE OF GLIBENCLAMIDE IN PREGNANCY (Date of issue: August 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Glibenclamide is an oral sulfonylurea hypoglycaemic agent indicated in the treatment of non-insulin-dependent diabetes (...) in patients who fail to respond to dietary measures alone. Glibenclamide may be used in conjunction with metformin or insulin. Glibenclamide may be considered in the treatment of gestational diabetes where metformin is ineffective or not tolerated, and where treatment with insulin is declined. Data on the use of glibenclamide in pregnancy consist of >9,500 exposures, although as glibenclamide is used in the management of gestational diabetes, first trimester exposure data are lacking and an increased risk

2014 UK Teratology Information Service

17. Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Full Text available with Trip Pro

Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to evaluate the effect of vildagliptin on endothelial function and arterial stiffness in patients with T2DM and hypertension.Fifty over 35-year-old (...) patients with T2DM and hypertension, without cardiovascular disease, will be randomly allocated to two groups: group 1 will receive vildagliptin added-on to metformin and group 2, glibenclamide added-on to metformin. Biochemical tests (glycemia, glycated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, triglycerides, creatinine, alanine aminotransferase, ultrasensitive C-reactive protein, and microalbuminuria), 24-h non-invasive ambulatory blood pressure monitoring, and assessment

2015 Diabetology & metabolic syndrome Controlled trial quality: uncertain

18. Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (GCC 1465)

5 days prior to the treatment planning MRI and WBRT is at least 4 days prior to registration). Greater than 40 pack year history of smoking cigarettes. Whole Brain Radiotherapy at least 4 days and no more than 1 year prior to registration. RPA Class III. Exclusion Criteria: Known sulfonylurea treatment within 7 days prior to registration. Sulfonylureas include glyburide/glibenclamide (Diabeta, Glynase); glyburide plus metformin (Glucovance); glimepiride (Amaryl); repaglinide (Prandin (...) Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (GCC 1465) Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2015 Clinical Trials

19. Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Full Text available with Trip Pro

Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Since antiquity bitter melon has been in use for treating diabetes but clinical trials show conflicting results about its usefulness. The present study aims to asses and compare the hypoglycemic and antiatherogenic effects as well as the safety of two different doses of bitter melon with glibenclamide.A total of 95 participants were randomized into 3 groups; group I and group II (...) received bitter melon (2 g/day and 4 g/day respectively) and group III received glibenclamide (5 mg/day) for 10 weeks. Glycemic control and antiatherogenic effects were determined by assessing glycohemoglobin (HbA1-c), fasting plasma glucose (FPG), 2 hour oral glucose tolerance test (OGTT), plasma sialic acid (PSA), systolic blood pressure (SBP), blood lipids and atherogenic index at different time periods.Compared to baseline, mean reduction in HbA1-c at the endpoint was significant among patients

2015 Nutrition journal Controlled trial quality: uncertain

20. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide - A randomised controlled trial. (Abstract)

Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide - A randomised controlled trial. Two oral hypoglycaemic agents, metformin and glibenclamide, have been compared with insulin in separate large randomised controlled trials and have been found to be as effective as insulin in gestational diabetes. However, very few trials have compared metformin with glibenclamide.Of 159 South Indian women with fasting glucose ≥5.5 mmol/l (...) and ≤7.2 mmol/l and/or 2-h post-prandial value ≥6.7 mmol/l and ≤13.9 mmol/l after medical nutritional therapy consented to be randomised to receive either glibenclamide or metformin. 80 women received glibenclamide and 79 received metformin. Neonatal outcomes were assessed by neonatologists who were unaware that the mother was part of a study and were recorded by assessors blinded to the medication the mother was given. The primary outcome was a composite of neonatal outcomes namely macrosomia

2015 The Australian & New Zealand journal of obstetrics & gynaecology Controlled trial quality: predicted high